Stricter Regulations for Online Prescription Drug Sales

🔑 Enhanced Key Takeaways

•The new guidelines, issued by China's National Medical Products Administration (NMPA) on May 25, 2026, explicitly mandate real-name purchases for all online prescription drugs and prohibit the reuse of the same prescription for multiple purchases.
•A significant aspect of the new regulations is the explicit ban on using artificial intelligence (AI) to conduct pharmacist reviews of prescriptions, requiring human oversight for medication safety.
•The online drug retail market in China has experienced rapid expansion, exceeding 80 billion yuan ($11.8 billion) in 2025, highlighting the substantial scale of the sector being impacted by these stricter rules.
•Certain high-risk products, including vaccines, blood products, narcotics, psychotropic medicines, toxic drugs, radioactive drugs, and precursor chemicals, are strictly prohibited from online sale.
•Third-party platforms facilitating online drug sales are now required to establish robust quality management systems, dedicated management departments, and employ qualified pharmaceutical professionals to oversee drug quality and distribution.

🛠️ Technical Deep Dive

Online drug retailers must establish systems for drug quality and safety management, risk control, drug traceability, storage and delivery management, adverse reaction reporting, and handling complaints.
Platforms are required to implement systems for drug information display, prescription review, real-name purchase of prescription drugs, and transaction record retention.
Online pharmaceutical service systems must be established by retailers, staffed by legally qualified pharmacists or other pharmaceutical technicians to examine and dispense prescriptions and guide rational drug use.
The use of artificial intelligence (AI) to conduct pharmacist reviews of prescriptions is explicitly banned.
Third-party platforms are encouraged to establish an automated information submission mechanism, such as an open data interface, with drug administrations.
Platforms must verify the qualifications of electronic prescription providers and sign agreements with them, and take effective measures to prevent the reuse of paper prescriptions.

🔮 Future ImplicationsAI analysis grounded in cited sources

Online health platforms will need to significantly restructure their operational models for prescription drug sales.

The new regulations mandating real-name purchases, stricter prescription reviews, and the ban on AI for pharmacist reviews will necessitate substantial changes to existing automated or semi-automated processes, increasing operational costs and complexity.

The market share of physical pharmacies in prescription drug sales may see a resurgence or stabilization.

Increased regulatory burdens and operational complexities for online platforms could shift consumer preference back towards traditional brick-and-mortar pharmacies, especially for urgent or complex prescription needs.

Innovation in AI applications for online pharmacy will be redirected away from direct pharmacist review functions.

With the explicit ban on AI for pharmacist reviews, companies will likely focus AI development on other areas such as supply chain optimization, customer service, or drug information dissemination, rather than core prescription verification.

⏳ Timeline

2019

China amended the Drug Administration Law to permit online sale of prescription drugs with certain limitations, marking the first national congress-level regulatory policy on online pharmacy.

2022-12-01

The Administrative Measures for Supervising Online Sales of Drugs took effect, officially allowing nationwide online sales of prescription drugs after regional pilot programs.

2022-12-01

China's National Medical Products Administration (NMPA) specified requirements for online drug sellers and platforms to file necessary information to local regulators.

2026-01-27

China's State Council published the amended Implementing Regulations of the Drug Administration Law (State Council Decree No. 828).

2026-05-15

The amended Implementing Regulations of the Drug Administration Law took effect, reinforcing oversight across the full lifecycle of drug products and clarifying platform responsibilities.

2026-05-25

China's top drug regulator issued new guidelines for online sales of prescription drugs, mandating real-name purchases and stricter prescription reviews, and explicitly banning AI for pharmacist reviews.